Title
Baylor St. Luke's Dr. Frazier Presented with Lifetime Achievement Award
Date
10/03/2017
Article
O. Howard Frazier, M.D., pioneer in transplant and circulatory support at Baylor St. Luke’s Medical Center, was presented with an award with the inscription, "A Celebration of Mechanical Circulatory Support Honoring Dr. O.H. Frazier," celebrating his numerous contributions to the field of mechanical circulatory support at the International Society of Heart & Lung Transplantation (ISHLT) at the U.S. National Archives in Washington, D.C. on April 27, 2016.

Dr. Frazier was also presented with a Lifetime Achievement Award in Life Sciences from the Houston Technology Center (HTC) on May 12, 2016. HTC advances the commercialization of emerging technology companies in the Houston area.

For more than 30 years, Dr. Frazier has been a pioneer in the treatment of severe heart failure and in the fields of heart transplantation and artificial devices that may be used either to substitute for or assist the pumping action of the human heart. As a result of his work, the Texas Heart Institute has become one of the top transplantation and mechanical circulatory support programs in the world. Dr. Frazier has performed over 1,200 heart transplants and implanted more than 1000+ left ventricular assist devices, more than any other surgeon in the world.

Dr. Frazier’s interest in mechanical circulatory support began in 1969, when, as a student at Baylor College of Medicine, he wrote a research paper about the experimental total artificial heart, which was first implanted in 1969 by Dr. Denton Cooley. Throughout the 1970s and 1980s, Dr. Frazier continued experimental work toward developing an implantable left ventricular assist device (LVAD) to aid the failing heart. He implanted the first LVAD in 1986 with the HeartMate I; since then this device has become the most widely used implantable LVAD in the world. In 2011, Dr. Frazier implanted the first successful continuous-flow total artificial heart using two second generation HeartMate II LVADs to replace a patient’s failing heart.

Subscribe